hs-CRP: Which Tests to Order Alongside It

What hs-CRP Actually Is, and What It Is Not

hs-CRP and standard CRP measure the same protein, C-reactive protein, made by the liver in response to interleukin-6 and other inflammatory signaling from fat tissue, atherosclerotic plaque, and injured or infected tissue. The difference is assay sensitivity. A standard CRP test is built to detect the large increases seen in infection or acute injury and typically cannot distinguish values under a few mg/L. The high-sensitivity assay resolves that lower range, which is where the cardiovascular and metabolic signal actually lives.

This is also why hs-CRP should not be confused with point-of-care CRP tests used in some primary care and urgent care settings to help decide whether a respiratory infection needs an antibiotic. Those tests are built for a different clinical question, at a different concentration range, evaluated with different study designs; one methodological paper on assessing the diagnostic impact of point-of-care CRP testing describes how that kind of evaluation is done and is a useful reference for understanding why a CRP-based test built for infection triage is not interchangeable with hs-CRP built for cardiovascular risk stratification (Riley et al., 2022).

The direct answer: hs-CRP below 1.0 mg/L is generally categorized as lower cardiovascular risk, 1.0 to 3.0 mg/L as intermediate, and above 3.0 mg/L as higher risk; a result above roughly 10 mg/L usually reflects an acute illness rather than chronic vascular inflammation and should be repeated after recovery before it is used for risk assessment. This three-tier framework traces back to a 2003 joint scientific statement from the CDC and American Heart Association on inflammatory markers and cardiovascular disease, and it remains the reference point most clinical guidelines cite, though readers should confirm they are looking at the version currently endorsed rather than an outdated summary.

The thesis: hs-CRP is a tie-breaker, not a diagnosis

The most defensible way to use hs-CRP is as a tie-breaker for a decision you already have to make, not as a stand-alone diagnosis of "inflammation." The 2008 JUPITER trial is the clearest illustration: in adults with LDL-C below 130 mg/dL, an hs-CRP at or above 2.0 mg/L identified a group that appeared to benefit from statin therapy despite looking low-risk by cholesterol numbers alone, and that trial is the reason cardiology guidelines now list hs-CRP as a factor that can tip a borderline statin decision. Outside that specific use case, an isolated hs-CRP value has weaker footing. The useful question is rarely "is hs-CRP high," but rather "what pattern of companion results explains why it's high, and does that pattern point to something actionable."

The tests worth ordering with it, and why

Fasting lipid panel and apolipoprotein B (ApoB)

A standard lipid panel and hs-CRP measure two different things: LDL-C estimates cholesterol mass carried by atherogenic particles, while hs-CRP estimates the vascular inflammatory response. JUPITER specifically enrolled people with normal LDL-C and elevated hs-CRP, which is why ordering both together, rather than either alone, is what actually reproduces the population that trial studied.

ApoB adds a layer LDL-C misses: each atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries one ApoB molecule, so ApoB is a closer proxy for particle count than cholesterol mass is. Several lipid guidelines favor ApoB as a secondary target in people with high triglycerides or metabolic syndrome, which is also the population where hs-CRP elevation is common. Ordering both together helps separate patients with particle burden and active inflammation (the higher-risk combination) from patients with elevated hs-CRP but a clean lipid profile.

Fasting insulin and glucose (for HOMA-IR)

Insulin resistance drives IL-6 release from fat tissue, which is upstream of hs-CRP. A fasting insulin and fasting glucose together allow calculation of HOMA-IR (fasting insulin × fasting glucose, divided by a constant). Observational cohorts have reported that hs-CRP tracks upward across HOMA-IR categories even in people whose fasting glucose is still normal, which is the practical reason to pair the two: insulin resistance can be present years before glucose crosses into the prediabetes range, and an elevated hs-CRP in that window can be an earlier signal than glucose alone. The exact magnitude of that association in any single cited study should be checked against the primary paper before it is quoted with a specific number.

HbA1c

HbA1c reflects average glucose over roughly three months and is used, per current ADA diagnostic criteria, to flag prediabetes (5.7 to 6.4%) and diabetes (6.5% or higher). Chronic hyperglycemia activates some of the same inflammatory pathways that raise hs-CRP, so an elevated hs-CRP alongside an HbA1c already in the prediabetes range is a reasonable prompt to prioritize lifestyle intervention, though HbA1c and hs-CRP are measuring related but distinct processes and neither substitutes for the other.

Thyroid-stimulating hormone (TSH)

Hypothyroidism, including subclinical hypothyroidism, is a correctable condition that has been associated with higher hs-CRP, higher LDL-C, and higher homocysteine at the same time in cross-sectional studies. Including TSH in an initial panel is inexpensive and avoids missing a single treatable cause behind several abnormal markers at once.

Homocysteine (situational)

Homocysteine is an independent cardiovascular marker whose proposed mechanism, direct endothelial injury and oxidative stress, is distinct from the cholesterol-driven and inflammation-driven pathways captured by ApoB and hs-CRP. Because the two markers rise through different biology, ordering both provides non-redundant information. Elevated homocysteine has been linked to B-vitamin and folate status and to MTHFR variants in some patients, though supplementation's effect on hard cardiovascular outcomes is less settled than its effect on the homocysteine number itself; that distinction matters and should not be glossed over.

Fibrinogen (situational)

Fibrinogen is a coagulation protein that also behaves as an acute-phase reactant, so it tends to rise alongside hs-CRP during inflammation and has been studied as an independent predictor of cardiovascular events. It is most useful as a confirmatory marker when hs-CRP is elevated and a clinician wants evidence of a prothrombotic pattern rather than an isolated inflammatory blip.

Lipoprotein(a) [Lp(a)] (once, generally)

Lp(a) is largely genetically fixed and not captured by a standard lipid panel. Multiple lipid societies recommend measuring it at least once in a person's lifetime because a high Lp(a) reclassifies lifetime cardiovascular risk regardless of LDL-C. Lp(a) particles carry oxidized phospholipids proposed to provoke vascular inflammation, which is a plausible mechanistic link to hs-CRP, though this is a mechanistic hypothesis rather than a settled causal chain. Checking it once helps explain persistent hs-CRP elevation in a patient whose LDL-C already looks well controlled on treatment.

Uric acid, CBC with differential, and sex hormones (situational)

Elevated uric acid has been associated with endothelial dysfunction and tends to co-occur with hs-CRP elevation in metabolic syndrome and gout; it is inexpensive and worth adding when those conditions are suspected. A CBC with differential does not measure inflammation directly but screens for occult infection, anemia, or a hematologic process that could be inflating hs-CRP for reasons unrelated to cardiovascular or metabolic disease, and is worth checking before attributing a persistently high hs-CRP to "metabolic inflammation" by default. Sex hormones (testosterone, estradiol, SHBG) are reasonable additions when fatigue, low libido, or unexplained body composition change suggest a hormonal driver; observational studies have linked lower testosterone in men and estrogen decline at perimenopause to higher hs-CRP, but these are associations from cross-sectional data, not proof that hormone therapy lowers cardiovascular risk through this pathway, and any such claim needs verification against the primary studies before it is used to justify treatment.

A pattern-based way to decide what to order next

Two patients can both have an hs-CRP of 2.4 mg/L and need completely different next steps. This framework is meant to guide that next step, not to replace clinical judgment.

The pattern, not the single number, is what should change what happens next. An hs-CRP of 2.4 mg/L with a clean metabolic and thyroid workup is a different clinical situation from the same number sitting next to elevated insulin, elevated ApoB, and a family history of early heart disease.

How hs-CRP is reported to change, and what that does and does not prove

Several interventions have been studied for their effect on hs-CRP:

• Statin therapy. Statins have been reported to lower hs-CRP by roughly 15 to 25% independent of their LDL-lowering effect, and this anti-inflammatory effect is part of the rationale cardiology guidelines give for using hs-CRP as a risk-enhancing factor. The JUPITER trial itself found a large relative reduction in cardiovascular events, commonly cited at around 44%, in its enrolled population; exact confidence intervals and secondary endpoints should be checked against the original 2008 NEJM publication rather than relied on from memory or secondary summaries.
• Weight loss. Trials of substantial weight loss, including the STEP 1 semaglutide trial, have reported meaningful improvements in inflammatory markers alongside weight reduction, consistent with visceral fat being a major source of the IL-6 that drives hs-CRP. This is an observed association within those trials, not proof that hs-CRP reduction itself is what lowers cardiovascular risk.
• Mediterranean-pattern diet. The PREDIMED trial found cardiovascular benefit from a Mediterranean diet supplemented with olive oil or nuts compared with a lower-fat control diet, and inflammatory markers including hs-CRP have been reported to improve in Mediterranean diet studies more broadly.
• Aerobic exercise. Exercise trials and meta-analyses have generally found modest reductions in hs-CRP with regular aerobic activity, roughly consistent with public health guidance of at least 150 minutes per week of moderate activity, though the specific effect size reported in any one meta-analysis should be verified before it is quoted precisely.
• High-dose omega-3 fatty acids. The REDUCE-IT trial found that high-dose icosapentaenoic acid reduced cardiovascular events in statin-treated patients with elevated triglycerides; some inflammatory marker changes were also reported in that trial, though the primary claimed benefit of REDUCE-IT was cardiovascular event reduction, not hs-CRP reduction specifically, and the two should not be conflated.

What is established: hs-CRP correlates with cardiovascular risk at a population level, and a handful of specific interventions (statins, substantial weight loss, Mediterranean-pattern eating, regular aerobic exercise) are associated with lower hs-CRP.

What is plausible but not proven: that lowering hs-CRP by itself, independent of the underlying condition causing it, directly reduces a given patient's cardiovascular risk. Most of the trial evidence supports treating the underlying driver (LDL-C, weight, blood pressure, glucose) with hs-CRP used as one input into that decision, not as a treatment target in its own right.

What is not established by anything in this article: a specific numeric target hs-CRP that every patient should be treated toward, or that correcting isolated hormonal or thyroid abnormalities reliably normalizes hs-CRP in every case. Those claims require individualized clinical evaluation.

Timing, fasting, and things that throw the number off

hs-CRP does not require fasting on its own, but it is commonly drawn alongside a fasting lipid panel and fasting insulin, so most people end up fasting anyway. Recent infection, vaccination within the past few weeks, surgery, pregnancy, oral contraceptive use, and active autoimmune flares can all raise hs-CRP through mechanisms unrelated to chronic cardiovascular risk, and a value above roughly 10 mg/L should prompt a look for one of these causes rather than immediate use in a risk calculation. In stable patients being followed over time, repeating hs-CRP every 6 to 12 months alongside a lipid panel is a reasonable general interval, though someone starting a new intervention (a statin, a weight-loss program, thyroid treatment) may reasonably be rechecked sooner, around 3 months, to see an early response.

When this is not the right test

hs-CRP cannot diagnose a specific disease, tell you whether pain or fatigue has an inflammatory cause, or replace imaging or a clinical exam when there is a concern for an acute process like appendicitis, a joint infection, or a flare of known autoimmune disease. A markedly high, unexplained CRP with fever, focal pain, weight loss, or other concerning symptoms warrants prompt clinical evaluation rather than repeat outpatient lab testing.